Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 11-12, 2006, Pages 1593-1601

  Marie, I ^a   Ducrotte, P ^a   Denis, P ^a   Hellot, M F ^a   Levesque, H ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANDIDIASIS; CONTROLLED STUDY; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS MUCOSA; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MANOMETRY; MOTOR DYSFUNCTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STOMACH POLYP; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ESOPHAGITIS; FEMALE; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROTON PUMPS; SCLERODERMA, SYSTEMIC;

EID: 33845477485     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03180.x     Document Type: Article

References (45)

1. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994; 24: 29-39.
2. Jiranek GC, Bredfelt JE. Organ involvement: gut and hepatic manifestations. In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Baltimore: Williams & Wilkins, 1996: 453-482.
3. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 346-54.
4. Marie I, Ducrotté P, Hellot MF, Denis P, Levesque H. Outcome of small bowel motor impairment in systemic sclerosis: a prospective manometric 5-year follow-up. Rheumatology 2006; epub ahead of print.
5. Marie I, Levesque H, Ducrotté P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001; 41: 1874-83.
6. Marie I, Levesque H, Ducrotté P, et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 1998; 96: 77-83.
7. Murphy JR, McNally P, Peller P, et al. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis. Dig Dis Sci 1992; 37: 833-41.
8. Sallam H, McNearney TA, Chen JDZ. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Phamacol Ther 2006; 23: 691-712.
9. Sjögren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265-82.
10. Sjögren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996; 8: 569-75.
11. Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis: a complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989; 149: 589-93.
12. Bassotti G, Battaglia E, Debernardi V, et al. Esophageal dysfunction in scleroderma. Relationship with disease subsets. Arthritis Rheum 1997; 40: 2252-9.
13. Zamost BJ, Hirschberg J, Ippoliti AF, et al. Esophagitis in scleroderma: prevalence and risk factors. Gastroenterology 1987; 92: 421-8.
14. Hendel L, Svejgaard E, Walsoe I, et al. Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand J Gastroenterol 1988; 23: 1182-6.
15. Subcommittee for scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
16. Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classi-fication, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
17. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
18. Hurwitz AL, Duranceau A, Postlethwait RW. Esophageal dysfunction and Raynaud's phenomenon in patients with scleroderma. Dig Dis 1976; 21: 601-6.
19. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
20. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-6.
21. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997; 92: 2012-6.
22. Basilisco G, Barbera R, Molgora M, et al. Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis. Gut 1993; 34: 1487-91.
23. Ling TC, Johnston BT. Esophageal investigations in connective tissue disease. Which tests are most appropriate? J Clin Gastroenterol 2001; 32: 33-6.
24. Bigard MA, Pelletier AL. Esophageal complications of non steroidal antiinflammatory drugs. Gastroenterol Clin Biol 2004; 28 (Suppl. 3): C58-C61.
25. Cryer B. Mucosal defense and repair: role of prostaglandins in the stomach and duodenum. Gastroenterol Clin North Am 2001; 30: 877-94.
26. Katzka DA, Reynolds JC, Saul SH, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med 1987; 82: 46-52.
27. Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis 2004; 22: 171-80.
28. Hillman LC, Chiragakis L, Shabolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's esophagus. Med J Aust 2004; 180: 387-91.
29. Csendes A, Smok G, Quiroz J, et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 2002; 97: 554-60.
30. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001; 96: 2005-12.
31. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004; 164: 1482-8.
32. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86-91.
33. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212-5.
34. Abraham SC, Singh VK, Yardley JH, Wu TT. Hyperplastic polyps of the esophagus and esophagogastric junction: histologic and clinicopathologic findings. Am J Surg 2001; 25: 1180-7.
35. Oguma J, Ozawa S, Omori T, et al. EMR of a hyperplastic polyp arising in ectopic gastric mucosa in the cervical esophagus: case report. Gastrointest Endosc 2001; 61: 335-8.
36. Takeji H, Ueno J, Nishitani H. Ectopic gastric mucosa in the upper esophagus: prevalence and radiologic findings. AJR Am J Roentgenol 1995; 164: 901-4.
37. Mion F, Lambert R, Partensky C, Cherkaoui M, Berger F. High-grade dysplasia in an adenoma of the upper esophagus developing on heterotopic gastric mucosa. Endoscopy 1996; 28: 633-5.
38. Shibahara K, Haraguchi Y, Sasaki I, et al. A case of gastric hyperplastic polyp with malignant transformation. Hepatogastroenterology 2005; 52: 319-21.
39. Takagi A, Ema Y, Horii S, Morishima M, Miyashi O, Kino I. Early adenocarcinoma arising from ectopic gastric mucosa in the cervical esophagus. Gastrointest Endosc 1995; 41: 167-70.
40. Marie I, Hachulla E, Chérin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53: 155-65.
41. Kasapidis P, Xynos E, Mantides A, et al. Differences in manometry and 24-H ambulatory pH-metry between patients with and without endoscopic or histological esophagitis in gastroesophageal reflux disease. Am J Gastroenterol 2002; 88: 1893-9.
42. Hendel L, Hage E, Hendel J, et al. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6: 565-77.
43. Meier-Sydow J, Weiss SM, Buhl R, et al. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994; 15: 77-96.
44. Tobin RW, Pope CE II, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1804-8.
45. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994; 121: 6-10.